Guidelines developed in partnership with
Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer. Sydney: Cancer Council Australia. [Version URL: http://wiki.cancer.org.au/australiawiki/index.php?oldid=122832, cited 2018 Feb 17]. Available from: https://wiki.cancer.org.au/australia/Guidelines:PSA_Testing/Prostate_biopsy_and_multiparametric_MRI.
National Health and Medical Research Council
In approving the guidelines (recommendations), NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years. NHMRC is satisfied that the guidelines (recommendations) are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.This publication reflects the views of the authors and not necessarily the views of the Australian Government.
When prostate biopsy is indicated for men with suspected prostate cancer, the optimal protocol for investigation involves determining:
The use of multiparametric magnetic resonance imaging (MRI) in men with elevated prostate-specific antigen (PSA) levels who have not yet undergone an initial biopsy is beyond the scope of this guideline.i
i This chapter focuses on the use of multiparametric MRI after a negative prostate biopsy, not on its use for the primary investigation of a positive PSA test, because this is not routine clinical practice.